Astria Therapeutics (NASDAQ:ATXS) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Astria Therapeutics (NASDAQ:ATXS) released its quarterly earnings results on Monday. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05), Yahoo Finance reports.

Astria Therapeutics Stock Down 4.9 %

Shares of Astria Therapeutics stock traded down $0.51 during trading on Wednesday, reaching $9.98. The company’s stock had a trading volume of 448,418 shares, compared to its average volume of 741,174. The company has a market cap of $548.03 million, a price-to-earnings ratio of -4.18 and a beta of 0.73. The firm’s 50-day moving average is $10.06 and its two-hundred day moving average is $11.38. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ATXS. TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective on the stock. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday. Finally, Oppenheimer increased their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.20.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.